Blood levels of lactate — a molecule involved in how the body produces energy — may help predict survival and short-term weight changes in people with amyotrophic lateral sclerosis (ALS), according to a new study from Australia and Japan. Researchers found that patients with lower blood lactate levels had…
News
AB Science has identified a new blood biomarker, produced by certain immune cells, that may help assess the activity of its experimental therapy masitinib in people with amyotrophic lateral sclerosis (ALS). The biomarker, which the company did not disclose for patent protection reasons, is capable of identifying patients…
Early birds — people with a natural tendency to wake up and go to sleep at earlier times — are significantly less likely to develop amyotrophic lateral sclerosis (ALS) than night owls, whose natural preference is to wake up and go to sleep at later times, according to a…
The experimental therapy QRL-201 successfully reached its biological target and showed early signs that it may slow disease progression in people with sporadic amyotrophic lateral sclerosis (ALS), according to new Phase 1/2 trial data. These interim results from the proof-of-concept ANQUR trial (NCT05633459) suggest the treatment can…
The Muscular Dystrophy Association (MDA) has launched its annual MDA Shamrocks campaign, described as the nation’s largest St. Patrick’s Day-themed fundraiser, to support people living with amyotrophic lateral sclerosis (ALS) and other rare neuromuscular diseases. During the campaign, held throughout February and March, thousands of retailers across the…
An assistant professor from the University of Nevada, Las Vegas, whose work focuses on the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS), has been named the first recipient of the MDA Research Momentum Award, a new honor from the Muscular Dystrophy Association (MDA) for early-career scientists. According to an MDA…
Early treatment with PrimeC, an experimental oral treatment being developed by Neurosense Therapeutics, significantly extended survival in people with amyotrophic lateral sclerosis (ALS) by more than 14 months compared with a six-month delay in treatment initiation. That’s according to additional long-term data from PARADIGM (NCT05357950), a completed…
The amyotrophic lateral sclerosis (ALS) community is mourning the loss of Eric Dane, the “Grey’s Anatomy” star who turned his personal battle with the disease into a crusade for a cure. Dane died Thursday at the age of 53, one year after a diagnosis that saw him trade his…
A U.S. biotech company’s experimental oral therapy, neflamapimod, designed to treat age-related brain disorders, has been selected for inclusion in the EXPERTS-ALS platform study, a U.K. initiative aiming to rapidly test potential treatments for amyotrophic lateral sclerosis (ALS). Developer Cervomed announced in a company press release that its treatment…
A triple combination therapy has shown promise for treating sporadic amyotrophic lateral sclerosis (ALS), according to a new study that used cell models of the disease to screen more than 100 therapeutic compounds. The new cell-based model was created from motor neurons, or nerve cells, derived from people with…
Recent Posts
- ALS caregivers across Canada can now access free professional counseling
- When an ALS caregiver takes a much-needed break from the daily routine
- Advocates push for swift passage of ACT for ALS reauthorization bill
- How to not get angry when trying to force a square peg into a round hole
- Shionogi completes acquisition of rights to ALS drug Radicava